Headache and combination estrogen-progestin oral contraceptives: Integrating evidence, guidelines, and clinical practice

Headache

Volumn 45, Issue 3, 2005, Pages 224-231

  Loder, Elizabeth W ^b   Buse, Dawn C ^b   Golub, Joan R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b and Red Sox Foundation and Massachusetts General Hospital Home Base Program   (United States)

Author keywords

Guidelines; Migraine; Oral contraceptives; Recommendations; Review

Indexed keywords

ESTROGEN; GESTAGEN;

CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FAMILY HISTORY; FEMALE; HEADACHE; HIGH RISK POPULATION; HUMAN; MEDICAL DECISION MAKING; MIGRAINE WITH AURA; ORAL CONTRACEPTION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TENSION HEADACHE; TREATMENT PLANNING;

ADULT; CONTRACEPTIVES, ORAL, COMBINED; ESTROGENS; FEMALE; HUMANS; MIGRAINE DISORDERS; PRACTICE GUIDELINES; PROGESTINS; RISK FACTORS;

EID: 15344339212     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2005.05049.x     Document Type: Review

References (34)

1. Herold ES, Goodwin MS. Perceived side effects of oral contraceptives among adolescent girls. Can Med Assoc J. 1980;123(10):1022-1026.
2. Rosenberg M, Waugh M. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol. 1998;179(3):577-582.
3. Petitti DB. Combination estrogen-progestin oral contraceptives. N Engl J Med. 2003;349:1443-1450.
4. Victory R. Adverse cardiovascular disease outcomes are reduced in women with a history of oral contraceptive use: results from the Women's Health Initiative Database. Abstract 0-130, Presented at the American Society for Reproductive Medicine Meeting, October 2004, Philadelphia, PA.
5. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346:2025-2032.
6. Lipton RB, Diamond S, Reed M, et al. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41:638-645.
7. Available at http://www.guideline.gov/summary/ summary.aspx?ss= 15&doc_id=2737&nbr=1963, accessed November 1,2004.
8. Carolei A, Marinir C, De Matteis G. Italian National Research Council Study on stroke in the young. Lancet. 1996;347:1503-1506.
9. Tzourio C, Tehindrazanarivelo A, Iglesias S, et al. Case control study of migraine and risk of ischemic stroke in young women. Br Med J. 1995;310:830-833.
10. Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. Br Med J. 1993;306:956-963.
11. Loder E, Buse D, Golub J. Headache as a side effect of oral contraceptives: a systematic review. Am J Obstet Gynecol. 2005 (in press).
12. Fitzgerald C, Feichtinger W, Spona J, et al. A comparison of the effects of two monophasic low dose oral contraceptives on the inhibition of ovulation. Adv Contracept. 1994;10:5-18.
13. Edelman DA, Kothenbeutel R, Levinski MJ, Kelly SE. Comparative trials of low-dose combined oral contraceptives. J Reprod Med. 1983;28:195-200.
14. Gerais AS, Rushwan H. A crossover pill study among Sudanese women. Int J Gynaecol Obstet. 1985;23:229-233.
15. Williams JK. Rationale for new oral contraceptive dosing, Int J Fertil Women's Med. 2004;49(l):30-35.
16. The use of hormonal contraception in women with co-existing medical conditions. ACOG Practice Bulletin No. 18. Int J Gynecol Obstet. 2001;75:93-106.
17. World Health Organization. Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use, 2nd ed. Geneva: World Health Organization; 2000.
18. Massiou H, MacGregor EA. Evolution and treatment of migraine with oral contraceptives. Cephalalgia. 2000;20:170-174.
19. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med. 2001;344:1132-1138.
20. Available at http://www.mircette.com/mircette.rl5. pdf, accessed January 7, 2004.
21. Silberstein S. Editorial commentary. Cephalalgia. 2000;20:145-146.
22. Granella F, Sances G, Pucci E, et al. Migriane with aura and reproductive life events: a case control study. Cephalalgia. 2000;20:701-707.
23. Larsson-Cohn U, Lundberg PO. Headache and treatment with oral contraceptives. Acta Neurol Scand. 1970;46:267-268.
24. Guillebaud J. The 150/30 formulation. Experience in the United Kingdom. J Reprod Med. 1983;28(suppl 1):66-70.
25. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population-a prevalence study. J Clin Epidemiol. 1991;44:1147-1157.
26. Tepper SJ, Dahlof CGH, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache. 2004;9:856-864.
27. Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol. 2000;95:261-266.
28. Whitty CWM, Hockaday JM, Whitty MM. The effect of oral contraceptives on migraine. Lancet. 1966;1:856-859.
29. Williams JK. Rationale for new oral contraceptive dosing. Int J Fertil Women's Med. 2004;49(1):30-35.
30. Available at http://www.seasonale.com/pi/default. asp?app.flash=0, accessed November 1, 2004.
31. Cachrimanidou AC, Hellberg D, Nilsson S, Waldenstrom U, Olsson SE, Sikström B. Long-interval treatment regimen with a desogestrel containing contraceptive. Contraception. 1993;48:205-216
32. Calhoun A. Adjusting estradiol concentrations reduces headache frequency and severity in female migraineurs. Cephalalgia. 2001;21:448-449.
33. MacGregor EA, Hackshaw A. Prevention of migraine in the pill-free week of combined oral contraceptives using natural oestrogen supplements. J Fam Plan Reprod Healthc. 2002;28(1):27-31.
34. International Headache Society Task Force. Recommendations on the use of oral contraceptives in women with migraine. Cephalalgia. 2000;20:155-156.